Back to search
FDAFDA · Food and drugs·Recall number D-0099-2025

Duloxetine Delayed-Release Capsules, USP, 20 mg, Rx only, 60 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-413-06

Published December 11, 2024 · Recall initiated: November 14, 2024

Summary

FDA records drug Class II recall D-0099-2025, published December 11, 2024 and initiated November 14, 2024. Recalling firm: Amerisource Health Services LLC; Status: Ongoing; Reported quantity: 37,916 bottles; Lot: Lots: DT2023001A, DT2023009A, exp date Jan 31, 2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Amerisource Health Services LLC
Distributor
PA, OH, PR
Lot
Lots: DT2023001A, DT2023009A, exp date Jan 31, 2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine Delayed-Release Capsules, USP, 20 mg, Rx only, 60 count bottles, Manufactured by: Aurobindo Pharma Limited, Hyderabad-500 090, India, For BluePoint Laboratories NDC 68001-413-06 recalled?

Yes. FDA published recall D-0099-2025 on December 11, 2024. Reported hazard: CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit

What should I do if I have this product?

Voluntary: Firm initiated · Letter